Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CONCETTA M FORCHETTI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184656852
CMS profile
189389
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$8,113.42

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $7,410.00 1
Piramal Imaging Limited $600.00 1
Biogen, Inc. $63.47 1
Genentech, Inc. $39.95 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CONCETTA M FORCHETTI

NPI 1184656852 · CMS profile ID 189389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184656852?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184656852?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184656852?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184656852?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $8,113.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $63.4712/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660609559 CMS
Genentech, Inc. $39.9504/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174503 CMS
Piramal Imaging Limited $600.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707744343 CMS
Merck Sharp & Dohme Corporation $7,410.0001/07/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695746877 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,113.42 4
PY2020 $565.00 1
PY2021 $38,624.37 33
PY2022 $15,350.00 6
PY2023 $16,660.79 32
PY2024 $39,378.02 40
PY2025 $50,287.88 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,463.90 81
PY2024 Principal investigator $630,831.36 79
PY2023 Recipient $591.95 2
PY2023 Principal investigator $1,785,779.63 92
PY2022 Recipient $10,066.00 2
PY2022 Principal investigator $1,648,640.76 51
PY2021 Recipient $1,310.44 2
PY2021 Principal investigator $1,377,364.84 65
PY2020 Recipient $2,195.35 2
PY2020 Principal investigator $1,008,121.30 81
PY2019 Recipient $294.51 1
PY2019 Principal investigator $1,007,212.44 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $256.00 12/29/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145847
Principal investigator 1 Janssen Research & Development, LLC $256.00 12/29/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145849
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 12/29/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145851
Principal investigator 1 Janssen Research & Development, LLC $256.00 12/29/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145855
Principal investigator 1 Janssen Research & Development, LLC $16,031.00 12/25/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145853
Principal investigator 1 Genentech, Inc. $3,958.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226449
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226463
Principal investigator 1 Genentech, Inc. $2,739.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226473
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226487
Principal investigator 1 Genentech, Inc. $3,863.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226495
Principal investigator 1 Genentech, Inc. $1,521.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226507
Principal investigator 1 Genentech, Inc. $1,676.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226519
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226529
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226541
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226553
Principal investigator 1 Genentech, Inc. $6,044.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226565
Principal investigator 1 Genentech, Inc. $1,010.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226577
Principal investigator 1 Genentech, Inc. $1,899.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226587
Principal investigator 1 Genentech, Inc. $2,920.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226600
Principal investigator 1 Genentech, Inc. $1,165.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226609
Principal investigator 1 Genentech, Inc. $5,106.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226619
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226625
Principal investigator 1 Genentech, Inc. $1,070.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226635
Principal investigator 1 Genentech, Inc. $5,408.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226645
Principal investigator 1 Genentech, Inc. $5,713.40 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226655
Principal investigator 1 Genentech, Inc. $1,010.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226663
Principal investigator 1 Genentech, Inc. $1,703.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226673
Principal investigator 1 Genentech, Inc. $1,831.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226683
Principal investigator 1 Genentech, Inc. $1,314.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226694
Principal investigator 1 Genentech, Inc. $1,010.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226705
Principal investigator 1 Genentech, Inc. $1,225.00 12/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226717
Principal investigator 1 Janssen Research & Development, LLC $3,035.00 11/20/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145845
Principal investigator 1 Genentech, Inc. $96.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226275
Principal investigator 1 Genentech, Inc. $96.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226283
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226295
Principal investigator 1 Genentech, Inc. $96.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226307
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226319
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226331
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226343
Principal investigator 1 Genentech, Inc. $96.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226355
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226367
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226375
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226387
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226399
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226411
Principal investigator 1 Genentech, Inc. $96.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226423
Principal investigator 1 Genentech, Inc. $50.00 11/14/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226435
Principal investigator 1 Janssen Research & Development, LLC $18,254.00 10/23/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145843
Principal investigator 1 Janssen Research & Development, LLC $2,696.00 10/06/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145841
Principal investigator 1 Eli Lilly and Company $1,314.20 10/01/2023 Non-covered Recipient Entity
YALE UNIVERSITY
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038150767
Principal investigator 1 Eli Lilly and Company $84.60 09/26/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038066891
Principal investigator 1 Janssen Research & Development, LLC $10,316.00 09/08/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145839
Principal investigator 1 Genentech, Inc. $1,464.00 08/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226241
Principal investigator 1 Genentech, Inc. $1,464.00 08/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226253
Principal investigator 1 Genentech, Inc. $1,070.00 08/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226265
Principal investigator 1 Janssen Research & Development, LLC $3,496.00 08/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145837
Principal investigator 1 Janssen Research & Development, LLC $600.00 07/31/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145833
Principal investigator 1 Janssen Research & Development, LLC $512.00 07/17/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145835
Principal investigator 1 Eli Lilly and Company $1,360.41 07/11/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038066215
Principal investigator 1 Eli Lilly and Company $153.00 07/11/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038083761
Principal investigator 1 Janssen Research & Development, LLC $9,728.00 07/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145831
Principal investigator 1 Genentech, Inc. $1,500.00 06/22/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226217
Principal investigator 1 Genentech, Inc. $1,100.00 06/22/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226229
Principal investigator 1 Janssen Research & Development, LLC $256.00 06/22/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145825
Principal investigator 1 Janssen Research & Development, LLC $3,035.00 06/12/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145827
Principal investigator 1 Janssen Research & Development, LLC $15,129.00 06/05/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145829
Principal investigator 1 Janssen Research & Development, LLC $256.00 05/29/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145823
Principal investigator 1 Janssen Research & Development, LLC $150.00 05/22/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145819
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/12/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145815
Principal investigator 1 Janssen Research & Development, LLC $256.00 05/12/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145817
Principal investigator 1 Eli Lilly and Company $15.48 05/10/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038066391
Principal investigator 1 Janssen Research & Development, LLC $16,547.00 05/08/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145813
Principal investigator 1 Janssen Research & Development, LLC $600.00 05/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145821
Principal investigator 1 Genentech, Inc. $2,076.00 05/02/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1052393597
Principal investigator 1 Eli Lilly and Company $7,822.25 04/25/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038068401
Principal investigator 1 Genentech, Inc. $298.00 04/20/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226205
Principal investigator 1 Eli Lilly and Company $12,000.00 04/18/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038083739
Principal investigator 1 Eli Lilly and Company $94,085.00 04/04/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038068395
Principal investigator 1 Janssen Research & Development, LLC $2,616.00 03/27/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145799
Principal investigator 1 Eli Lilly and Company $1,923.11 03/20/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038070787
Recipient Eli Lilly and Company $236.95 03/08/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038048795
Principal investigator 1 Janssen Research & Development, LLC $11,385.00 03/06/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145803
Principal investigator 1 Janssen Research & Development, LLC $25.00 02/16/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145801
Principal investigator 1 Janssen Research & Development, LLC $300.00 02/13/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145805
Principal investigator 1 Janssen Research & Development, LLC $234.00 02/13/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145807
Principal investigator 1 Janssen Research & Development, LLC $250.00 02/13/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145811
Recipient Eli Lilly and Company $355.00 01/31/2023 Covered Recipient Physician A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038050409
Principal investigator 1 Janssen Research & Development, LLC $8,388.00 01/30/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986145809
Principal investigator 1 Eli Lilly and Company $20.72 01/26/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038065889
Principal investigator 1 Eli Lilly and Company $1,878.56 01/26/2023 Non-covered Recipient Entity
STEVEN A DAVIS M D
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038154251
Principal investigator 1 Genentech, Inc. $5,634.40 01/13/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1040226191
Principal investigator 1 Biogen, Inc. $744,917.00 01/12/2023 Non-covered Recipient Entity
Alexian Brothers Health Systems Inc
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1012172891
Principal investigator 1 Biogen, Inc. $316,805.50 01/12/2023 Non-covered Recipient Entity
Alexian Brothers Health System
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1012177701
Principal investigator 1 Eli Lilly and Company $401,693.00 01/03/2023 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038066885